- Home
- QRED vs TARA Comparison
QRED vs TARA Comparison
Compare QRED & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$2.47
Company Overview
Basic Information| Metric | QRED | TARA |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.8M | 159.6M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | QRED | TARA |
|---|---|---|
| Price | $10.11 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $25.33 |
| AVG Volume (30 Days) | 17.7K | ★ 913.4K |
| Earning Date | N/A | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.93 | $2.09 |
| 52 Week High | $10.10 | $7.82 |
Technical Indicators
Market Signals| Indicator | QRED | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 65.95 | 43.64 |
| Support Level | $10.02 | $2.28 |
| Resistance Level | N/A | $2.63 |
| Average True Range (ATR) | 0.01 | 0.19 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 99.89 | 59.81 |
Price Performance
Historical Comparison QRED
TARA
About QRED QuasarEdge Acquisition Corporation Ordinary Shares
QuasarEdge Acquisition Corp is a newly organized blank check company.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.